-

HEALTHCARE REALTY INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Healthcare Realty Trust Incorporated - HR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Healthcare Realty Trust Incorporated (NYSE: HR) (“the Company”) with Healthcare Trust of America, Inc. (NYSE: HTA) pursuant to which each share of HR common stock will be exchanged for one share of HTA common stock at a fixed ratio. In addition, HTA shareholders will receive a total implied value of $35.08 per share comprised of a special cash dividend of $4.82 per share and a transaction exchange ratio of 1:1 based on HR’s unaffected price of $30.26 on February 24, 2022. At closing, HR and HTA shareholders will own 39% and 61% of the combined company, respectively.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-hr/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, 855-768-1857
KSF Managing Partner
lewis.kahn@ksfcounsel.com

Industry:

Kahn Swick & Foti, LLC

NYSE:HR
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, 855-768-1857
KSF Managing Partner
lewis.kahn@ksfcounsel.com

More News From Kahn Swick & Foti, LLC

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led to it...

Trip.com 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Trip.com Group Limited - TCOM

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 11, 2026 to file lead plaintiff applications in a securities class action lawsuit against Trip.com Group Limited (NasdaqGS: TCOM) (“Trip.com” or the “Company”), if they purchased or otherwise acquired the Company’s securities between April 30, 2024 and January 13, 2026, inclusive (the “Class Period”...

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”).On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engi...
Back to Newsroom